Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...

Full description

Bibliographic Details
Main Authors: Manuela Basso, Saravanan S.Karuppagounder, Jürgen Rohr, Rajiv R. Ratan, Jill Berlin, Sama F. Sleiman
Format: Article
Language:English
Published: MDPI AG 2011-08-01
Series:Pharmaceuticals
Subjects:
mithramycin A
HDAC inhibition
Myc
neurons
oxidative stress
Online Access:http://www.mdpi.com/1424-8247/4/8/1183/

Internet

http://www.mdpi.com/1424-8247/4/8/1183/

Similar Items